Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Adults (≥18 years)
• Patients receiving or scheduled to receive anti-SARS-CoV-2 and/or anti-MPXV vaccines or monoclonal antibodies
• Patients have provided written informed consent
Locations
Other Locations
France
CHU Orléans
RECRUITING
Orléans
Contact Information
Primary
Thierry PRAZUCK, Dr
thierry.prazuck@chu-orleans.fr
0238229593
Time Frame
Start Date: 2025-08-22
Estimated Completion Date: 2035-07-11
Participants
Target number of participants: 30
Treatments
Other: Participants receiving vaccines and/or monoclonal antibodies
Participants receive standard-of-care SARS-CoV-2 and/or MPXV vaccines or monoclonal antibodies. This study does not assign the treatment but collects biosamples to assess antibody response.
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Régional d'Orléans